Select publications

Ghielmini M et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103(12):4416-23. Abstract

Hainsworth JD et al. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma — A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23(6):1088-95. Abstract

Halaas JL et al. The Follicular Lymphoma International Prognostic Index (FLIPI) is superior to WHO/REAL histological grade for identifying high-risk patients: A retrospective review of the MSKCC experience in 260 patients with follicular lymphoma. Proc ASH 2004;Abstract 3268.

Kaminski MS et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352(5):441-9. Abstract

Press OW et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003;102(5):1606-12. Abstract

Zelenetz AD et al. Initial Treatment of Mantle Cell Lymphoma with Sequential Radioimmunotherapy with Tositumoamb/Iodine I131 I-Tositumoamb followed by CHOP Chemotherapy Results in a High Complete Remission Rate. Proc ASH 2003;Abstract 1477.